A5101745325- Bone health and treatments
- Bone Metabolism and Diseases
- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Connective tissue disorders research
- Parathyroid Disorders and Treatments
- Fibroblast Growth Factor Research
- Bone health and osteoporosis research
- Cancer, Hypoxia, and Metabolism
- Iron Metabolism and Disorders
- Neurogenetic and Muscular Disorders Research
- TGF-β signaling in diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- Wnt/β-catenin signaling in development and cancer
- Hemoglobinopathies and Related Disorders
- Esophageal and GI Pathology
- Angiogenesis and VEGF in Cancer
- Cancer, Lipids, and Metabolism
- Erythrocyte Function and Pathophysiology
- Amoebic Infections and Treatments
- Trace Elements in Health
- Genetic and Kidney Cyst Diseases
- Protein Kinase Regulation and GTPase Signaling
- Cerebrovascular and genetic disorders
- Cancer Diagnosis and Treatment
New York University
2017-2024
Inserm
2010-2018
Université Paris Cité
2010-2016
Sorbonne Paris Cité
2014-2016
Délégation Paris 7
2010-2015
Centre Hospitalier des Pays de Morlaix
2014
Université de Reims Champagne-Ardenne
2012-2014
Institut des Vaisseaux et du Sang
2009-2014
Hôpital Lariboisière
2010-2014
Biomatériaux et Inflammation en Site Osseux
2013
Stimulating bone formation is an important challenge for anabolism in osteoporotic patients or to repair defects. The osteogenic properties of matrix glycosaminoglycans (GAGs) have been explored; however, the functions GAGs at surface bone-forming cells are less documented. Syndecan-2 a membrane heparan sulfate proteoglycan that associated with osteoblastic differentiation. We used transgenic mouse model high syndecan-2 expression osteoblasts enrich cellular GAGs. Bone mass was increased...
Abaloparatide, a novel analog of parathyroid hormone-related protein (PTHrP 1-34), became in 2017 the second osteoanabolic therapy for treatment osteoporosis. This study aims to compare effects PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling male mice. Intermittent daily subcutaneous injections 80 μg/kg/d were administered 4-month-old C57Bl/6J mice 6 weeks. During treatment, followed by DXA-Piximus assess changes mineral density (BMD) whole body, femur, tibia. At either 4 or...
Voltage-dependent potassium (Kv) channels are tetramers of six transmembrane domain (S1–S6) proteins. Crystallographic data demonstrate that the tetrameric pore (S5–S6) is surrounded by four voltage sensor domains (S1–S4). One key question remains: how do sensors (S4) regulate gating? Previous mutagenesis obtained on Kv channel KCNQ1 highlighted critical role specific residues in both S4-S5 linker (S4S5L) and S6 C terminus (S6T). From these data, we hypothesized S4S5L behaves like a ligand...
The bone catabolic actions of parathyroid hormone (PTH) are seen in patients with hyperparathyroidism, or infusion PTH rodents. We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediator PTH's anabolic effects on bone. To determine its role effects, we continuously infused female wild-type (WT) and MCP-1-/- mice hPTH vehicle. Microcomputed tomography (µCT) analysis cortical showed hPTH-infusion induced significant loss WT mice. Further, μCT...
Hypoferremia results as an acute phase response to infection and inflammation aiming reduce iron availability pathogens. Activation of toll-like receptors (TLRs), the key sensors innate immune system, induces hypoferremia mainly through rise hormone hepcidin. Conversely, stimulation erythropoiesis suppresses hepcidin expression via induction erythropoietin-responsive erythroferrone. Iron deficiency stimulates transcription osteocyte-secreted protein FGF23. Here we hypothesized that FGF23 in...
Intermittent administration of parathyroid hormone (PTH) 1–34 at a standard dose has been shown to induce anabolic effects in bone. However, whether low-dose PTH promotes bone formation during senescence is unknown. To address this issue, we determined the and analysed underlying mechanisms prematurely senescent mice that display osteopenia. Treatment 9-week-old Samp6 for 6 weeks with (100 μg/kg per day) increased vertebral femoral mass improved microarchitecture as result bone-forming...
Patients with cystic fibrosis (CF) display low bone mass and alterations in formation. Mice carrying the F508del genetic mutation conductance regulator (Cftr) gene reduced formation decreased mass. However, underlying molecular mechanisms leading to these skeletal defects are unknown, which precludes development of an efficient anti-osteoporotic therapeutic strategy. Here we report a key role for intermediate filament protein keratin 8 (Krt8), osteoblast dysfunctions F508del-Cftr mice. We...
Background and Aims. An arterial blood supply phenotypic changes of the sinusoids characterise liver vasculature in human hepatocellular carcinoma (HCC). We investigated effects rosuvastatin on vessel anomalies, tumour growth survival HCC. Methods. treated transgenic mice developing HCC, characterized by anomalies similar to those with rosuvastatin. Results. In group, time was longer (P < .001), weight .01) nodule surface were reduced. Rosuvastatin decreased number smooth muscle...
Renal anemia is a common complication in chronic kidney disease (CKD), associated with decreased production of erythropoietin (EPO) due to loss function, and subsequent red blood cell (RBC) production. However, many other factors play critical role the development renal anemia, such as iron deficiency, inflammation, elevated fibroblast growth factor 23 (FGF23) levels. We previously reported that inhibition FGF23 signaling rescues mice CKD. In present study we sought investigate whether...
Teriparatide (PTH (1-34)), PTHrP (1-36), and abaloparatide (ABL) have been used for the treatment of osteoporosis, but their efficacy long term is significantly limited. The 3 peptides exert time- dose-dependent differential responses in osteoblasts, leading us to hypothesize they may also differentially modulate osteoblast transcriptome. Treatment mouse calvarial osteoblasts with 1 nM 4 hours results RNA sequencing data PTH (1-34) regulating 367 genes, including 194 unique genes; (1-36) 117...
A number of studies have reported an association between phosphorus, red blood cell (RBC) production, and iron metabolism. However, it is difficult to distinguish whether the effect phosphorus direct or through actions FGF23, not clear positively negatively associated with RBC production. In present study, we investigated effects a) increased load b) deficiency on erythropoiesis metabolism in FGF23. Mice were fed either a 1.2% 1.65% diet compared mice control containing 0.6% phosphorus....
Abstract Introduction: Hepatocellular carcinoma (HCC), is characterized by severe vessel anomalies with an intense arterial blood supply (arterialisation), and acquisition ofa basal membrane rich in laminin sinusoids(sinusoid capillarisation). A role of the VEGF-A/Dll4-Notch4/ephrin B2 cascade tumor has been demonstrated, raising question nature theVEGF receptor pathway implicated triggering this cascade. This study was aimed at determining whether PlGF/VEGFR-1 or VEGF-A/VEGFR-2 pathways...
Abstract Teriparatide (PTH(1-34)) and its analogs, PTHrP(1-36) abaloparatide (ABL) have been used for the treatment of osteoporosis, but their efficacy over long-term use is significantly limited. The 3 peptides exert time- dose-dependent differential responses in osteoblasts, leading us to hypothesize that they may also differentially modulate osteoblast transcriptome. We show mouse calvarial osteoblasts with 1 nM 4 h results RNA-Seq data PTH(1-34) regulating 367 genes, including 194 unique...